DNMT3A and acute lymphoblastic leukemia: Treatment of T-ALL cells with 1 μM YM155 for 48 hours revealed a dramatic decrease in viability of DNMT3A-mutant cells with minimal impact on wild-type DNMT3A cells (Figure 7C-D).